Market Place
Sourcing Support
Risks of Picato for actinic keratosis outweigh benefits
30 Apr 2020 //
EMA
EMA confirms skin cancer risk with LEO`s Picato
20 Apr 2020 //
PHARMATIMES
EMA Begins Publishing All Health Professional Communications
14 Feb 2020 //
RAPS
Ingenol mebutate gel: suspension of the licence due to risk of skin malignancy
13 Feb 2020 //
GOVUK
LEO issues Picato recall
01 Feb 2020 //
PHARMA TIMES
Ingenol mebutate gel (Picato?): increased incidence of skin tumours seen
18 Oct 2019 //
MHRA
EMA Begins Review of Skin Cancer Data for Patients Using Picato
06 Sep 2019 //
RAPS
Perrigo UK Finco`s Generic Ingenol Mebutate Receives Approval in US
08 Jan 2019 //
FDA
Perrigo Uk Finco`s Generic Ingenol MebutateReceives Tentative Approval in US
09 Oct 2018 //
FDA
Actavis’s Generic Ingenol Mebutate Receives Approval In US
09 Feb 2018 //
FDA
Perrigo UK Finco Generic Ingenol Mebutate Receives Approval In US
03 Nov 2017 //
FDA
Perrigo Confirms First To File Patent Challenge For Generic Version Of Picato
13 Jun 2016 //
PR NEWSWIRE
Leo Pharma’s new chemical entity picato subject of paragraph IV
04 May 2016 //
TWO FOUR INSIGHT
Europe, US, Japan: The recall round-up
27 Aug 2015 //
IN-PHARMA TECHNOLOGIST
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.